Wen Yahong, Liao Grace, Pritchard Thomas, Zhao Ting-Ting, Connelly Jon P, Pruett-Miller Shondra M, Blanc Valerie, Davidson Nicholas O, Madison Blair B
From the Division of Gastroenterology, Washington University School of Medicine, Saint Louis, Missouri 63110.
First Hospital of China Medical University, Department of Breast Surgery, Shenyang, China 110001.
J Biol Chem. 2017 Apr 14;292(15):6148-6162. doi: 10.1074/jbc.M117.777722. Epub 2017 Feb 22.
The discovery and application of CRISPR/Cas9 technology for genome editing has greatly accelerated targeted mutagenesis in a variety of organisms. CRISPR/Cas9-mediated site-specific cleavage is typically exploited for the generation of insertions or deletions (indels) after aberrant dsDNA repair via the endogenous non-homology end-joining (NHEJ) pathway or, alternatively, for enhancing homology-directed repair to facilitate the generation of a specific mutation (or "knock-in"). However, there is a need for efficient cellular assays that can measure Cas9/guide RNA activity. Reliable methods for enriching and identifying desired mutants are also lacking. Here we describe a method using the transposon for stable genomic integration of an H2B-GFP reporter or a hygromycin resistance gene for assaying Cas9 target cleavage and homology-directed repair. The H2B-GFP fusion protein provides increased stability and an obvious pattern of nuclear localization. This method, called SRIRACCHA ( a table, but eversible, ntegrated eporter for ssaying RISPR/as-stimulated DR ctivity), enables the enrichment of mutants via selection of GFP-positive or hygromycin-resistant mammalian cells (immortalized or non-immortalized) as a surrogate for the modification of the endogenous target site. Currently available hyperactive transposase mutants allow both delivery and removal of the surrogate reporters, with minimal risk of generating undesirable mutations. This assay permits rapid screening for efficient guide RNAs and the accelerated identification of mutant clones and is applicable to many cell types. We foresee the utility of this approach in contexts in which the maintenance of genomic integrity is essential, for example, when engineering cells for therapeutic purposes.
CRISPR/Cas9基因组编辑技术的发现与应用极大地加速了多种生物体中的靶向诱变。CRISPR/Cas9介导的位点特异性切割通常用于通过内源性非同源末端连接(NHEJ)途径进行异常双链DNA修复后产生插入或缺失(Indel),或者用于增强同源定向修复以促进特定突变(或“敲入”)的产生。然而,需要能够测量Cas9/引导RNA活性的高效细胞检测方法。目前也缺乏富集和鉴定所需突变体的可靠方法。在这里,我们描述了一种使用转座子将H2B-GFP报告基因或潮霉素抗性基因稳定基因组整合的方法,用于检测Cas9靶点切割和同源定向修复。H2B-GFP融合蛋白具有更高的稳定性和明显的核定位模式。这种方法称为SRIRACCHA(用于检测CRISPR/Cas刺激的DR活性的可翻转整合报告基因),通过选择GFP阳性或潮霉素抗性哺乳动物细胞(永生化或非永生化)作为内源性靶位点修饰的替代物,实现突变体的富集。目前可用的高活性转座酶突变体允许替代报告基因的递送和去除,产生不良突变的风险最小。该检测方法允许快速筛选高效引导RNA并加速突变体克隆的鉴定,适用于多种细胞类型。我们预见这种方法在维持基因组完整性至关重要的情况下的实用性,例如,在为治疗目的改造细胞时。